Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Systemic Lupus Erythematosus Clear all
Recruiting Phase 1 Interventional

US Zamto-cel Autoimmune Diseases

NCT06708845
View directory record Official record
Conditions
Lupus Nephritis, Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Diffuse Cutaneous Systemic Sclerosis
Interventions
zamtocabtagene autoleucel, Cyclophosphamide, Fludarabine
Biological · Drug
Lead sponsor
Miltenyi Biomedicine GmbH
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sirolimus for Autoimmune Disease of Blood Cells

NCT00392951
View directory record Official record
Conditions
Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS), Evans Syndrome, Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune, Autoimmune Neutropenia, Lupus Erythematosus, Systemic, Inflammatory Bowel Disease, Rheumatoid Arthritis
Interventions
sirolimus
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
1 Year to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

NCT05638802
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
DS-7011a, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Anniston, Alabama • North Little Rock, Arkansas • North Miami Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 1 Interventional

Safety Study of AMG 557 in Subjects With Lupus Arthritis

NCT01683695
View directory record Official record
Conditions
Lupus Arthritis, Systemic Lupus Erythematosus
Interventions
AMG 557, Matching Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
4
States / cities
Los Angeles, California • San Leandro, California • Danbury, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Jul 22, 2026, 5:59 AM EDT
Terminated Phase 1 Interventional

An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)

NCT01689025
View directory record Official record
Conditions
Inflammation, Systemic Lupus Erythematosus
Interventions
NNC0114-0006, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
La Jolla, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Results available

Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease

NCT01753401
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Acthar, Placebo, Steroid Drug
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
22
States / cities
Jonesboro, Arkansas • La Jolla, California • La Palma, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Jul 22, 2026, 5:59 AM EDT
Terminated Not applicable Interventional

Physical Therapy for Systemic Lupus Erythematosus (SLE)

NCT00152555
View directory record Official record
Conditions
Lupus Erythematosus, Systemic, SLE
Interventions
Physical Therapy or Relaxation Therapy
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
16 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Jul 22, 2026, 5:59 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

NCT05620407
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
39
States / cities
La Jolla, California • La Mesa, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Jul 22, 2026, 5:59 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus

NCT00008749
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
13 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 22, 2026, 5:59 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine

NCT00775476
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
12
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 22, 2026, 5:59 AM EDT
Recruiting Not applicable Interventional

Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus

NCT06232304
View directory record Official record
Conditions
Systemic Lupus Erythematosus of Childhood (Disorder)
Interventions
TEACH
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
12 Years to 22 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • New Orleans, Louisiana • Grand Rapids, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Jul 22, 2026, 5:59 AM EDT
Completed No phase listed Observational

A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US

NCT05337124
View directory record Official record
Conditions
Lupus Nephritis
Interventions
LUPKYNIS
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
South Gate, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2025 · Synced Jul 22, 2026, 5:59 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis

NCT04221477
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Obinutuzumab, MMF, Prednisone, Placebo, Methylprednisolone, Acetaminophen, Diphenhydramine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2031
U.S. locations
18
States / cities
Birmingham, Alabama • Beverly Hills, California • Fontana, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 5:59 AM EDT
Not listed Early Phase 1 Interventional

Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE

NCT04726553
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE)
Interventions
Anifrolumab, Standard of Care
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
New Haven, Connecticut • Atlanta, Georgia • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Jul 22, 2026, 5:59 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

NCT03517722
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Placebo, Ustekinumab (approximately 6 mg/kg), Ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
16 Years to 75 Years
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
69
States / cities
Anniston, Alabama • Birmingham, Alabama • Vestavia Hills, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 22, 2026, 5:59 AM EDT
Recruiting Phase 2 Interventional

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

NCT07409181
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
BI 3000202, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 74 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
30
States / cities
Beverly Hills, California • La Palma, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Magnetic Resonance Spectroscopy, Perfusion and Diffusion Tensor Imaging in Neuropsychiatric Lupus

NCT00723671
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Fibromyalgia, Acute Neuropsychiatric Lupus
Interventions
MRI
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Jul 22, 2026, 5:59 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

NCT06576271
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
GSK4527363, Placebo matching GSK4527363, Belimumab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
6
States / cities
Scottsdale, Arizona • Aurora, Colorado • Las Vegas, Nevada + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 22, 2026, 5:59 AM EDT
Active, not recruiting Phase 1 Interventional

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

NCT06294236
View directory record Official record
Conditions
Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis
Interventions
SC291
Biological
Lead sponsor
Sana Biotechnology
Industry
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jul 22, 2026, 5:59 AM EDT
Active, not recruiting Phase 2 Interventional

Daratumumab to Treat Active Lupus Nephritis

NCT04868838
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Daratumumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 22, 2026, 5:59 AM EDT
Completed No phase listed Observational Results available

Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry

NCT01729455
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Benlysta, Standard of Care (SoC) Therapy
Biological · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
3,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
102
States / cities
Birmingham, Alabama • Glendale, Arizona • Goodyear, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Jul 22, 2026, 5:59 AM EDT
Recruiting Phase 1 Interventional

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

NCT07201558
View directory record Official record
Conditions
Rheumatoid Arthritis, Systemic Lupus Erythematosus
Interventions
Surovatamig
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Birmingham, Alabama • Fullerton, California • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 5:59 AM EDT
Active, not recruiting Phase 1 Interventional

AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus

NCT06265220
View directory record Official record
Conditions
Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE
Interventions
AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab
Drug
Lead sponsor
Artiva Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Tucson, Arizona • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Jul 22, 2026, 5:59 AM EDT
Recruiting No phase listed Observational

Lupus Landmark Study: A Prospective Registry and Biorepository

NCT05934149
View directory record Official record
Conditions
Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus
Interventions
Not listed
Lead sponsor
Lupus Research Alliance
Other
Eligibility
18 Years to 110 Years
Enrollment
3,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
19
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 22, 2026, 5:59 AM EDT